← Back to Search

rTMS for Anxiety Disorders

N/A
Recruiting
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during session (approx. 45 minutes)
Awards & highlights

Study Summary

This trial is exploring if a device that changes brain activity can help people with anxiety better cope with fear or anxious situations. The study involves 3 visits, during which participants will do tasks while their brain activity is measured. If you qualify and participate, you can expect the visits to last 2-4 hours each.

Who is the study for?
This trial is for adults aged 18-65 who are fluent in English, currently seeking mental health treatment, and diagnosed with an anxiety disorder or related condition. It's not suitable for those on certain medications, pregnant individuals, people with metal implants (due to MRI), history of seizures or severe brain injury, substance abuse issues, psychotic disorders or bipolar mania.Check my eligibility
What is being tested?
The study tests if repetitive Transcranial Magnetic Stimulation (rTMS) can influence coping mechanisms in anxious situations. Participants will undergo rTMS and perform tasks that measure their reaction to emotional stimuli over three visits lasting up to four hours each at the Medical University of South Carolina.See study design
What are the potential side effects?
While this study isn't a treatment trial and focuses on reactions to emotional stimuli post-rTMS application, potential side effects from rTMS may include discomfort at the stimulation site, headache, lightheadedness or seizures in very rare cases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during session (approx. 45 minutes)
This trial's timeline: 3 weeks for screening, Varies for treatment, and during session (approx. 45 minutes) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Fear-Potentiated Startle Reflex
Change in Speed to Initiate Avoidance Behavior
Secondary outcome measures
Change in Approach/ Avoidance Conflict Electroencephalography
Change in Difficulty of Avoiding Task-Based Aversive Exposure
Change in Escape/ Avoidance Electroencephalography
+4 more
Other outcome measures
Task-Related Brain Activation

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neurostimulation GroupExperimental Treatment1 Intervention
On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day. Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation (rTMS)
2019
Completed Phase 2
~780

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Repetitive Transcranial Magnetic Stimulation (rTMS) works by rapidly turning a focused magnetic field on and off over the head, which temporarily increases brain activity in targeted areas. This mechanism is significant for patients with anxiety disorders because it can modulate neural circuits involved in anxiety, potentially reducing symptoms. By directly influencing brain activity, rTMS offers a non-invasive alternative for patients who may not respond well to traditional treatments like medication or psychotherapy, providing a new avenue for symptom relief.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,799 Previous Clinical Trials
2,661,084 Total Patients Enrolled
158 Trials studying Anxiety Disorders
65,320 Patients Enrolled for Anxiety Disorders
Medical University of South CarolinaLead Sponsor
940 Previous Clinical Trials
7,396,914 Total Patients Enrolled
14 Trials studying Anxiety Disorders
983 Patients Enrolled for Anxiety Disorders

Media Library

Repetitive Transcranial Magnetic Stimulation (rTMS) Clinical Trial Eligibility Overview. Trial Name: NCT04824105 — N/A
Anxiety Disorders Research Study Groups: Neurostimulation Group
Anxiety Disorders Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation (rTMS) Highlights & Side Effects. Trial Name: NCT04824105 — N/A
Repetitive Transcranial Magnetic Stimulation (rTMS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04824105 — N/A
~27 spots leftby Dec 2025